A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan
NCT04043975 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 286
Last updated 2025-02-14
Summary
The purpose of the observational study is to evaluate the safety and effectiveness of combination therapy with nivolumab and ipilimumab in Japanese participants with advanced or metastatic renal cell carcinoma (aRCC) in the real-world setting in Japan.
Conditions
- Advanced or Metastatic Renal Cell Carcinoma
Sponsors & Collaborators
-
Ono Pharmaceutical Co. Ltd
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-09-19
- Primary Completion
- 2024-08-23
- Completion
- 2024-08-23
Countries
- Japan
Study Locations
More Related Trials
-
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
NCT02231749 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
NCT04513522 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread
NCT03663946 ·Status: COMPLETED
-
Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
NCT03117309 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
NCT04088500 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults
NCT05361434 ·Status: ACTIVE_NOT_RECRUITING
-
Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure
NCT07117409 ·Status: TERMINATED
-
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
NCT03297593 ·Status: COMPLETED ·Phase: PHASE2
-
Prospective Translational Study Investigating Predictors of Outcome in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab (I-Rene Trial)
NCT04891055 ·Status: UNKNOWN
-
Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
NCT03013335 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
NCT03203473 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
NCT03075423 ·Status: COMPLETED ·Phase: PHASE2
-
Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
NCT05124431 ·Status: UNKNOWN ·Phase: PHASE2
-
Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma
NCT03469713 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.
NCT04134182 ·Status: UNKNOWN ·Phase: PHASE2
-
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
NCT03126331 ·Status: COMPLETED ·Phase: PHASE2
-
An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
NCT02596035 ·Status: COMPLETED ·Phase: PHASE4
-
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
NCT01472081 ·Status: COMPLETED ·Phase: PHASE1
-
Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
NCT06345183 ·Status: COMPLETED
-
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03937219 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma
NCT06472895 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
NCT01354431 ·Status: COMPLETED ·Phase: PHASE2
-
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
NCT04413123 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
NCT02853344 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
NCT03647878 ·Status: ACTIVE_NOT_RECRUITING